ArticleJournal of pharmacy & bioallied sciences2025
Safety and Efficacy of Oral Mifepristone for Cervical Ripening in Single Live Intrauterine Term Unscarred Pregnancies.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mifepristone results in cervical ripening in females undergoing pregnancy termination. It causes cervical ripening via blockage of progesterone receptors. Aim: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies. Methods: The present study assessed 200 single live-term intrauterine unscarred pregnancies. All were induced using oral mifepristone in 400 mg dose after assessment of BS. A reassessment of BS was done after 24 hours and if needed (in BS < 6), 0.5 mg instilled dinoprostone was given intracervical in 1-3 doses at 6-hour intervals. In BS > 6, subjects were sent to the labor room for oxytocin infusion and ARM, if needed. BS gains after 24 hours, perinatal outcomes, delivery route, and induction to delivery interval were assessed. Results: The mean birth weight in study subjects was 2862.5 ± 85.2 grams. delivery mode was cesarean, outlet forceps delivery, ventouse delivery, and normal delivery in 8.5% ( Conclusions: Mifepristone is efficacious and safe for inducing labor and cervical ripening in subjects with full-term pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.